A study involving patients with acute coronary syndrome, PCSK9-REACT (Reactivity in Patients with Acute Coronary Syndrome Treated with Prasugrel and Ticagrelol), confirmed that higher plasma PCSK9 levels are associated with greater platelet reactivity and a higher risk of thrombotic events from atherosclerotic plaque within 1 year of an acute coronary syndrome event [120]. This evidence concerns the gene PCSK9 and acute coronary syndrome.